Consensus $167.56M. The company said, “The company decreased its 2025 full-year revenue, increased its gross margin percentage and reduced its operating expense guidance as follows: Revenue in the range of $120.0 million to $130.0 million, revised downward from the previous guidance range of $160.0 million to $175.0 million, representing an implied decrease of 14% to 7% compared to 2024; Gross margin in the range of 72% to 74%, an increase from the previous guidance range of 71% to 73%, and representing an implied increase of 130 basis points to 330 basis points compared to 2024; Operating expense in the range of $145.0 to $155.0 million, representing an implied increase of 7% to 14% compared to 2024; Operating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight sees Q2 revenue $33.6M, consensus $39.78M
- RxSight Re-elects Directors at Annual Meeting
- RxSight’s Positive Momentum and Strategic Growth Initiatives Support Buy Rating
- Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks
- Netflix, Reddit downgraded: Wall Street’s top analyst calls